Increasing the Levels of Insulin-Like Growth Factor-I by an IGF Binding Protein Inhibitor Produces Anxiolytic and Antidepressant-Like Effects
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
The present studies were conducted to determine if increasing central levels of the neurotrophic factor insulin-like growth factor-1 (IGF-I) either directly or indirectly produces anxiolytic and antidepressant-like effects in the mouse. Central levels of IGF-I can be increased directly, by administering IGF-I, or indirectly by blocking the insulin-like growth factor binding proteins (IGFBPs). The IGFBP family has the unique ability to regulate IGF-I levels by sequestering IGF-I into an inactive complex. Therefore, an IGFBP inhibitor increases the level of IGF-I available to bind to its receptor. Intracerebroventricular (icv) administration of the nonspecific IGFBP inhibitor NBI-31772 (10-30 microg) increases the number of punished crossings in the four-plate test and NBI-31772 (0.3-10 microg) increases time spent in the open quadrant of the elevated zero maze (EZM), indicative of anxiolytic-like effects. NBI-31772 (3-30 microg) also decreases immobility time in the tail suspension test, indicative of antidepressant-like effects. Similarly, icv administration of IGF-I (0.1 microg) produces anxiolytic-like effects in the four-plate test and IGF-1 (0.3-1 microg) produces anxiolytic-like effects in the EZM. IGF-I (10 microg) also produces antidepressant-like effects in the tail suspension test. Coadministration of the IGF-I receptor antagonist JB1 with NBI-31772 or IGF-I blocks the anxiolytic-like and antidepressant-like effects of these compounds. These results suggest that NBI-…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, an increase of peripheral IGF-1 by direct injection of IGF-1 or inhibition of IGF-1 binding protein displayed anxiolytic and antidepressant effects in rodents (Duman et al. 2009; Hoshaw et al. 2005; Malberg et al. 2007; Park et al. 2011)”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Malberg et al. 2007
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391 · cited 1×
“Despite the high prevalence of depressive and anxiety disorders in the population (Berton and Nestler, 2006; Kessler et al, 2005; Malberg and Schechter, 2005), our understanding of the mechanisms by which antidepressant and anxiolytic drugs produce their effects are limited.”
BackgroundValidation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822 · cited 1×
“Compounds that increase the percentage time an animal spends in the open quadrants Neuropsychopharmacology of the EZM, compared to the closed quadrants, are considered to exhibit anxiolytic-like activity (Kash et al, 1999; Pellow et al, 1985).”
BackgroundThe tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534 · cited 1×
“The procedure followed in this study is a variant of the one originally described by Steru et al (1985).”
MethodNestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111 · cited 1×
“This difference in time course between the acute behavioral effects and the chronic administration necessary for cell proliferation has also been seen with clinically effective antidepressant such as fluoxetine (Malberg et al, 2000).”
BackgroundSelf-citationNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“Despite the high prevalence of depressive and anxiety disorders in the population (Berton and Nestler, 2006; Kessler et al, 2005; Malberg and Schechter, 2005), our understanding of the mechanisms by which antidepressant and anxiolytic drugs produce their effects are limited.”
BackgroundThe Somatomedin Hypothesis: 2001
Le Roith, D., Bondy, C., Yakar, S., Liu, J.-L., & Butler, A. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.1.0419 · Cited by 1,257 · cited 1×
“IGF-I was first named ‘somatomedin C’ owing to its ability to mediate the effect of somatotropin (growth hormone) (Le Roith et al, 2001).”
BackgroundBrunet, A., Datta, S. R., & Greenberg, M. E. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00211-7 · Cited by 1,188 · cited 1×
“This receptor signaling pathway activates both the Ras/mitogen-activated protein kinase pathway and the PI3 kinase–AKT pathways (Brunet et al, 2001; Ye and D’Ercole, 2006).”
BackgroundPeripheral Infusion of IGF-I Selectively Induces Neurogenesis in the Adult Rat Hippocampus
Åberg, M. A. I., Åberg, N. D., Hedbäcker, H., Oscarsson, J., & Eriksson, P. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02896.2000 · Cited by 852 · cited 2×
“It has been shown that IGF-I produces increases in cell proliferation and neurogenesis in vivo (Aberg et al, 2000).”
BackgroundShepherd, J. K., Grewal, S. S., Fletcher, A., Bill, D. J., & Dourish, C. T. (1994) · Psychopharmacology · doi:10.1007/bf02244871 · Cited by 739 · cited 2×
“The EZM is a modification of the elevated plus maze and consists of a circular platform (outer diameter approximately 60 cm, width 5 cm) that is elevated 55 cm above the floor, and made of black Perspex (Shepherd et al, 1994).”
Background
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Mechanisms and Functional Implications of Adult Neurogenesis
Zhao, C., Deng, W., & Gage, F. H. (2008) · Cell · doi:10.1016/j.cell.2008.01.033 · Cited by 3,007
“Similarly, infusion of IGF1 elicits anxiolytic and antidepressant-like effects in behavioral tests (Malberg et al., 2007), and systematic administration of IGF1 increases SGZ neurogenesis (see references in Duman and Monteggia, 2006).”
Sex-Specific Programming of Offspring Emotionality after Stress Early in Pregnancy
Mueller, B. R., & Bale, T. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1424-08.2008 · Cited by 988
“Reductions in growth factors have been linked to affective and neurodevelopmental disorders (Malberg et al., 2007).”
BackgroundFunctional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
Schmidt, H. D., Shelton, R. C., & Duman, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.151 · Cited by 474
“Chronic antidepressant administration increases IGF-1 expression in the rat brain (Khawaja et al, 2004), and IGF-1 regulates adult hippocampal neurogenesis (Anderson et al, 2002) and produces antidepressant behavioral responses (Hoshaw et al, 2005; Malberg et al, 2007).”
BackgroundNeurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
Metadata
- Authors
- Malberg, J. E., Platt, B., Rizzo, S. J. S., Ring, R. H., Lucki, I., Schechter, L. E., & Rosenzweig-Lipson, S.
- Affiliations
- Wyeth (US)
- University of Pennsylvania (US)
- Corresponding author
- Malberg, Jessica E
- Venue
- Neuropsychopharmacology
- Published
- 2007-03-07
- Volume
- 32
- Issue
- 11
- Pages
- 2360-2368
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1977606691
- Cited by
- 101
- References
- 47
- Citations by year
- 2026: 2 · 2025: 4 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 9 · 2015: 6 · 2014: 4 · 2013: 9 · 2012: 3
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 72832, U01MH072832)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- insulin-like growth factor I, anxiolytic effects, antidepressant effects, IGF-1 receptor, neurotrophic factors, depression, anxiety, intracerebroventricular administration, elevated zero maze, tail suspension test, four-plate test
- MeSH terms
- Analysis of Variance, Animals, Antidepressive Agents, Anxiety, Avoidance Learning, Behavior, Animal, Catechols, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Interactions, Enzyme Inhibitors, Gene Expression Regulation, Injections, Intraventricular, Insulin-Like Growth Factor I, Isoquinolines, Male, Motor Activity, Insulin-Like Growth Factor Binding Proteins, Hindlimb Suspension, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increasing the Levels of Insulin-Like Growth Factor-I by an IGF Binding Protein Inhibitor Produces Anxiolytic and Antidepressant-Like Effects. https://app.cochat.ai/papers/10.1038/sj.npp.1301358
- The paper
- Malberg, J. E., Platt, B., Rizzo, S. J. S., Ring, R. H., Lucki, I., Schechter, L. E., & Rosenzweig-Lipson, S. (2007). Increasing the Levels of Insulin-Like Growth Factor-I by an IGF Binding Protein Inhibitor Produces Anxiolytic and Antidepressant-Like Effects. Neuropsychopharmacology. https://doi.org/10.1038/sj.npp.1301358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.